There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Biogen Inc. has divulged 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of autoimmune disease and multiple sclerosis.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology ...

Biogen Idec, Inc., and Biocon Limited. In any market research analysis, the main field is competition. This segment of the report provides a competitive scenario and portfolio of the Oncology ...

On Wednesday, Goldman Sachs (NYSE:GS) reiterated its Buy rating on Biogen (NASDAQ:BIIB) with a maintained price target of $290.00. The firm's analysis acknowledged Biogen's ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.